AmplatzerTM Duct Occluders

AMPLATZER Patent Ductus Arteriosus

Features of Abbott’s Industry-Leading AmplatzerTM PDA Line1

While offering various options for patent ductus arteriosus (PDA) occluder therapy, the AmplatzerTM devices share certain characteristics:

  • Provide secure positioning in the ductus
  • Achieve complete closure
  • Promote tissue in-growth
  • Provide flexibility and conformability

AMPLATZERTM DUCT OCCLUDER: FOR LARGE PDA CLOSURE

Backed by a 15-year track record of performance in the U.S.,1 the Amplatzer Duct Occluder can accommodate large PDAs with a single device—which can aid in minimizing the complexity of the procedure.

Features include:

  • Data showing more than 98% complete occlusion at 6 and 12 months2
  • A cone shape that can help conform to tapering ducts
  • A retention skirt to prevent embolization

Its treatment range:

  • Ductus diameter: 3.0-12.0 mm 
  • Ductus length: > 3.0 mm*


* The AmplatzerTM Duct Occluder can be used in any length defect as long as the device does not extend more than 3 mm into the pulmonary artery or does not occupy over half of the pulmonary artery lumen.

AMPLATZERTM DUCT OCCLUDER II: Versatility to Conform to a Variety of PDAs

The AmplatzerTM Duct Occluder II is engineered using 2 articulating discs and multi-layered mesh that conforms to most classifications of PDAs.

Features include:

  • Symmetrical design so it can be introduced via pulmonary or aortic approach3
  • 6 planes of occlusion for full, cross-sectional coverage4
  • Fabric-free design allows for delivery through a low-profile catheter—while still achieving a very high occlusion rate3

A prospective study of the AmplatzerTM Duct Occluder II found that implantation is simple and the ability for retrograde aortic delivery revealed a statistically significant reduction in fluoroscopy time and therefore procedure-related radiation exposure.4

The study furthermore noted a very high rate of complete shunt resolution and a very low rate of complications.4

Its treatment range:

  • Ductus diameter: 2.5-5.5 mm
  • Ductus length: > 5.0-12.0 mm

AMPLATZER PICCOLOTM: FOR PDA CLOSURE

The Amplatzer PiccoloTM Occluder is able to occlude a variety of duct sizes, while minimizing protrusion into the aorta and pulmonary artery.

Features include:

  • Low-profile retention discs and end screw—specifically for small anatomy
  • Symmetrical design for either pulmonary or aortic approach  
  • Tightly woven mesh to minimize residual shunt immediately after positioning
  • Flexible delivery wire for ease of deployment
     

 

More Details on Patent Ductus Arteriosus

Find out more about the patients who benefit from treatment.
 

more

AP2947054-WBU Rev. A

References
  1. Data on file at Abbott.
  2. Amplatzer Duct Occluder IFU.
  3. Saliba Z, et al. The Amplatzer Duct Occluder II: a new device for percutaneous ductus arteriosus closure. J Interven Cardiol. 2009;22:496–502.
  4. Gruenstein DH, et al. Transcatheter closure of patent ductus arteriosus using the Amplatzer Duct Occluder II (ADO II). Catheter Cardiovasc Interv. 2017;89:1118–1128.  doi: 10.1002/ccd.26968.
Important safety information
  • AMPLATZER™ DUCT OCCLUDER

    AMPLATZERTM DUCT OCCLUDER AND DELIVERY SYSTEM
    INDICATIONS AND USAGE

    The AMPLATZERTM Duct Occluder is a percutaneous, transcatheter occlusion device intended for the nonsurgical closure of a patent ductus arteriosus (PDA).

    CONTRAINDICATIONS

    • Patients weighing less than 6 kg
    • Patients less than 6 months of age
    • Presence of thrombus at the intended site of implant, or documented evidence of venous thrombus in the vessels through which access to the defect is gained
    • Active endocarditis or other infections producing bacteremia
    • Patients whose vasculature, through which access to the defect is gained, is inadequate to accommodate the appropriate sheath size
    • Patients with pulmonary hypertension with pulmonary vascular resistance of greater than 8 Wood units or Rp/Rs of greater than 0.4

    WARNINGS

    • The device should be removed if greater than 3 mm extends into the pulmonary artery, or if more than half of the left pulmonary artery lumen is occupied by the device.
    • There is limited clinical data for patients over 40 years of age.
    • The AMPLATZERTM Duct Occluder and 180° Delivery System should only be used by those physicians trained in transcatheter defect closure techniques.
    • Physicians must be prepared to deal with urgent situations which require removal of embolized devices that result in critical hemodynamic compromise. This includes the availability of an on-site surgeon. 
    • Embolized devices must be removed. Embolized devices should not be withdrawn through intracardiac structures unless they have been adequately collapsed within a sheath.
    • Do not use if the sterile barrier has been compromised in any way.
    • Do not release the AMPLATZERTM Duct Occluder from the delivery cable if the device does not conform to its original configuration or if the device position is unstable. Recapture the device and redeploy. If still unsatisfactory, recapture the device and replace with a new device.

    PRECAUTIONS

    Handling
    The AMPLATZERTM Duct Occluder and 180° Delivery System were sterilized with ethylene oxide and are for single use only. Do not reuse or resterilize. Attempts to resterilize this device can cause a malfunction,  insufficient sterilization, or harm to the patient.

    Sizing
    Accurate defect sizing is crucial and mandatory for AMPLATZER™ Duct Occluder device selection. Refer to Table 4 for sizing instructions.

    Procedural

    • This device contains nickel-titanium alloy, which is generally considered safe. However, in vitro testing has demonstrated that nickel is released from this device for a minimum of 60 days. Patients who are allergic to nickel may have an allergic reaction to this device, especially those with a history of metal allergies. Certain allergic reactions can be serious; patients should be instructed to seek medical assistance immediately if they suspect they are experiencing an allergic reaction. Symptoms may include difficulty in breathing or swelling of the face or throat. While data is currently limited, it is possible that some patients may develop an allergy to nickel if this device is implanted. Some forms of nickel have also been associated with carcinogenicity (ability to cause cancer) in animal models. In humans, carcinogenicity has been demonstrated only through an inhalation route (breathing nickel in) which will not occur with this procedure.
    • The physician should exercise clinical judgment in situations that involve the use of anticoagulants or antiplatelet drugs before, during, and/or after the use of this device.

    Post-implant

    • Endocarditis prophylaxis is carried out for 6 months according to the recommendation of the American Heart Association. The decision to continue endocarditis prophylaxis beyond 6 months is at the discretion of the physician.
    • Any patient who has a residual shunt will undergo an echo cardiographic evaluation of the residual shunt until complete closure of the defect has been confirmed.
    • Lung perfusion scan should be completed if flow through is greater than 3 m/s, or if the Z-score is -2 for the left pulmonary artery diameter.
    • MR Conditional to 3.0 Tesla
      Through nonclinical testing, the AMPLATZERTM device has been known to be MR Conditional at field strengths of 3.0 tesla or less with a maximum whole-body-averaged specific absorption rate (SAR) of 3.83 W/kg at 1.5 tesla and 5.57 W/kg at 5.0 tesla for a 20-minute exposure to a B1 of 118μ tesla. The AMPLATZERTM device should not migrate in this MR environment. Nonclinical testing has not been performed to rule out the possibility of migration at field strengths higher than 3.0 tesla.
      In this testing, the device produced a temperature rise of 1.1°C at 1.5 tesla and 1.6°C at 5.0 tesla.
      MR image quality may be compromised if the area of interest is in the exact same area or relatively close to the position of the device.

    Use in Specific Populations

    • Pregnancy — Care should be taken to minimize the radiation exposure to the fetus and the mother.
    • Nursing mothers — There has been no quantitative assessment of the presence of leachables in breast milk.

    POTENTIAL ADVERSE EVENTS

    Placement of the AMPLATZERTM Duct Occluder involves using standard interventional cardiac catheterization techniques. In addition to the above observed adverse events, the following are potential adverse events listed in alphabetical order that were not observed in the clinical study.

    The following events might occur from either the catheterization procedure or from the device:

    • Air embolus
    • Allergic drug reaction
    • Allergic dye reaction
    • Anesthesia reactions
    • Apnea
    • Arrhythmia
    • Bacterial endocarditis
    • Bleeding
    • Brachial plexus injury
    • Chest pain
    • Death
    • Delivery system failure
    • Fever
    • Headache/migraine
    • Hypertension/hypotension
    • Myocardial infarction
    • Partial obstruction of aorta
    • Partial obstruction of pulmonary artery
    • Perforation of vessel or myocardium
    • Peripheral embolism
    • Stroke/transient ischemic attack
    • Thrombus
    • Valvular regurgitation
    • Vascular access site complications
  • AMPLATZER™ DUCT OCCLUDER II

    AMPLATZERTM DUCT II OCCLUDER
    INTENDED FOR USE


    The AMPLAZTERTM Duct Occluder II is a percutaneous transcatheter occlusion intended for the non-surgical closure of patent ductus arteriosus.

    CONTRAINDICATIONS

    The AMPLATZERTM Duct Occluder II is contraindicated for the following: 

    • Patients weighing less than 6 kg
    • Patients less than 6 months of age
    • Patients with a window-type patent ductus arteriosus (ie, length less than 3mm)
    • Patients with an active infection • Patients with thrombus at the intended site of implant
    • Patients with pulmonary hypertension with pulmonary vascular resistance of greater than 8 Wood units or Rp/Rs of greater than 0.4
    • Patients with patent ductus arteriosus greater than 12 mm in length by angiography
    • Patients with patent ductus arteriosus greater than 5.5 mm in diameter by angiography

    WARNINGS

    • Patients at greater risk of complications can include:
      • Patients with descending aorta < 10 mm in diameter
      • Patients with cardiac anomalies requiring surgical or interventional correction
      • Patients with have had more than 2 lower respiratory infections within the last year
    • Do not release the occluder from the delivery wire if the occluder does not conform to its original configuration or if the occluder position is unstable. Recapture the occluder and redeploy. If still unsatisfactory, recapture the occluder and replace with a new occluder.
    • The AMPLATZERTM Duct Occluder II should only be used by physicians trained in transcatheter defect closure techniques.
    • Physicians must have an on-site surgeon available in the event the surgical removal of an occluder is required.
    • Embolized occluders must be removed. Embolized occluders should not be withdrawn through intracardiac structures unless they have been adequately collapsed within a catheter.
    • This device has not been studied in patients older than 18 years of age.

    PRECAUTIONS

    • For single use only. Do not reuse or re-sterilize.
    • This device was sterilized with ethylene oxide and is for single use only. Do not use or re-sterilize this device. Attempts to re-sterilize this device can cause a malfunction, insufficient sterilization, or harm to the patient.
    • Use before the expiration date noted on the product packaging.
    • Patients should have an activated clotting time (ACT) of greater than 200 sec prior to device replacement.
    • The AMPLATZERTM Duct Occluder II contains nickel-titanium alloy, which is generally considered safe. However, in vitro testing has demonstrated that nickel is released from this device for a minimum of 60 days. Patients who are allergic to nickel may have an allergic reaction to this device, especially those with a history of metal allergies. Certain allergic reactions can be serious; patients should be instructed to seek medical assistance immediately if they suspect they are experiencing an allergic reaction. Symptoms may include difficulty in breathing or swelling of the face or throat. While data are currently limited, it is possible that some patients may develop an allergy to nickel if this device is implanted.
    • Use in specific populations
      • Pregnancy – Care should be taken to minimize the radiation exposure to the fetus and the mother.
      • Nursing mothers – There has been no quantitative assessment of the presence of leachables in breast milk.
    • Store in a dry place.
    • Do not use if the packaging sterile barrier is opened or damaged.
    • Do not use contrast power injection with delivery catheter.

    MR CONDITIONAL

    St. Jude Medical’s AMPLATZERTM Duct Occluder II device is manufactured of chemically etched nitinol wire, 80% platinum 20% iridium marker band and a 316L end screw.

    Non-clinical testing has demonstrated that the AMPLATZERTM Duct Occluder II device is MR-Conditional. Patients can be scanned safely immediately after implantation under the following conditions:

    • Static magnetic field of 1.5 Tesla (1.5T) or 3.0 Tesla (3.0T).
    • Maximum spatial gradient field less than or equal to 30 T/m.
    • Maximum whole-body-averaged specific absorption rate (SAR) of 2.0 W/kg (normal operating mode) for 15 minutes of scanning.

    In non-clinical testing with body coil excitation, the AMPLATZERTM Duct Occluder II device produced a differential temperature rise of less than or equal to 3.65°C when exposed to a maximum average whole body specific absorption rate (SAR) of 3.35 W/kg for 15 minutes of scanning in a 3.0 Tesla MR system (SiemensTM MAGNETOM EspreeTM, SYNGOTM MR B17 software, Erlangen, Germany). Scaling of the SAR and observed heating indicates that average whole body SAR of 2.0 W/kg would be expected to yield a localized temperature rise of less than or equal to approximately 1.0°C in Normal Operating Mode.

    In non-clinical testing with body coil excitation, the AMPLATZERTM Duct Occluder II device produced a differential temperature rise of less than or equal to 1.91°C when exposed to a maximum average whole body specific absorption rate (SAR) of 2.80 W/kg for 15 minutes of scanning in a 1.5 Tesla MR system (SiemensTM MAGNETOM EspreeTM, SYNGOTM MR B17 software, Erlangen, Germany). Scaling of the SAR and observed heating indicates that average whole body SAR of 2.0 W/kg would be expected to yield a localized temperature rise of less than or equal to approximately 1.0°C in Normal Operating Mode.

    MR Image quality may be compromised if the area of interest is the same or relatively close to the position of the device. Therefore, it may be necessary to optimize the MR imaging parameters for the presence of this implant.

    POTENTIAL ADVERSE EVENTS

    Potential adverse events that may occur during or after a procedure using this device may include, but are not limited to:

    Air embolus; Allergic dye reaction; Allergic drug reaction; Anesthesia reactions; Apnea; Arrhythmia; Bacterial endocarditis; Bleeding; Cardiac perforation; Cardiac tamponade; Chest pain; Device embolization; Device erosion; Death; Fever; Headache/migraine; Hypertension; Hypotension; Myocardial infarction; Palpitations; Pericardial effusion; Pericarditis; Peripheral embolism; Pleural effusion; Pulmonary embolism; Reintervention for device removal; Stroke; Transient ischemic attack; Thrombus; Valvular regurgitation; Vascular access site injury; and Vessel perforation.

  • AMPLATZER PICCOLO™ OCCLUDER

    AMPLATZER PICCOLOTM OCCLUDER
    INDICATIONS AND USAGE


    The AMPLATZER PiccoloTM Occluder is a percutaneous, transcatheter occlusion device intended for the nonsurgical closure of a patent ductus arteriosus (PDA).

    CONTRAINDICATIONS

    • Weight < 700 grams at time of the procedure
    • Age < 3 days at time of procedure
    • Coarctation of the aorta
    • Left pulmonary artery stenosis
    • Cardiac output that is dependent on right to left shunt through the PDA due to pulmonary hypertension
    • Intracardiac thrombus that may interfere with the implant procedure
    • Active infection requiring treatment at the time of implant
    • Patients with a PDA length smaller than 3 mm
    • Patients with a PDA diameter that is greater than 4 mm at the narrowest portion

    WARNINGS

    • This device was sterilized with ethylene oxide and is for single use only. Do not reuse or re-sterilize this device. Attempts to resterilize this device can cause a malfunction, insufficient sterilization, or harm to the patient.
    • Do not use the device if the sterile package is open or damaged.
    • Use on or before the last day of the expiration month that is printed on the product packaging label.
    • Patients who are allergic to nickel can have an allergic reaction to this device.
    • Prepare for situations that require the removal of this device. Preparation includes access to a transcatheter snare kit and an on-site surgeon.
    • Accurate measurements of the ductus are crucial for correct occluder size selection.
    • Do not release the occluder from the delivery wire if either a retention disc protrudes into the pulmonary artery or aorta; or if the position of the occluder is not stable.
    • Remove embolized devices. Do not remove an embolized occluder through intracardiac structures unless the occluder is fully recaptured inside a catheter.

    PRECAUTIONS

    • This device should be used only by physicians who are trained in standard transcatheter techniques. Determine which patients are candidates for procedures that use this device.
    • The physician should exercise clinical judgment in situations that involve the use of anticoagulants and antiplatelet drugs before, during, and/or after the use of this device.
    • Patients should have an activated clotting time (ACT) of greater than 200 sec prior to device placement, unless the patient has a significant risk for bleeding and is unable to be anti-coagulated.
    • The device may be delivered via an anterograde (venous) or a retrograde (arterial) approach. However, in small infants (≤2 kg), the device should be delivered using the anterograde (venous) approach since small infants are at an increased risk for arterial injury.
    •  The AMPLATZER PiccoloTM Occluder contains nickel-titanium alloy, which is generally considered safe. However, in vitro testing has demonstrated that nickel is released from this device for a minimum of 60 days following implant. Patients who are allergic to nickel may have an allergic reaction to this device, especially those with a history of metal allergies. Certain allergic reactions can be serious; patients should seek immediate medical attention if there is suspicion of an allergic reaction. Symptoms may include difficulty in breathing or swelling of the face or throat. While data are currently limited, it is possible that some patients may develop an allergy to nickel if this device is implanted.
    • Use in specific populations
      • Pregnancy — Minimize radiation exposure to the fetus and the mother.
      • Nursing mothers — There has been no quantitative assessment for the presence of leachables in breast milk.
    • Store in a dry place.
    • Do not use contrast power injection with delivery catheter.

    MR CONDITIONAL

    St. Jude Medical’s AMPLATZERTM Duct Occluder II device is manufactured of chemically etched nitinol wire, 80% platinum 20% iridium marker band and a 316L end screw.

    Non-clinical testing has demonstrated that the AMPLATZERTM Duct Occluder II device is MR-Conditional. Patients can be scanned safely immediately after implantation under the following conditions:

    • Static magnetic field of 1.5 Tesla (1.5T) or 3.0 Tesla (3.0T).
    • Maximum spatial gradient field less than or equal to 30 T/m.
    • Maximum whole-body-averaged specific absorption rate (SAR) of 2.0 W/kg (normal operating mode) for 15 minutes of scanning.

    In non-clinical testing with body coil excitation, the AMPLATZERTM Duct Occluder II device produced a differential temperature rise of less than or equal to 3.65°C when exposed to a maximum average whole body specific absorption rate (SAR) of 2.80 W/kg for 15 minutes of scanning in a 1.5 Tesla MR system (SiemensTM MAGNETOM EspreeTM, SYNGOTM MR B17 software, Erlangen, Germany). Scaling of the SAR and observed heating indicates that average whole body SAR of 2.0 W/kg would be expected to yield a localized temperature rise of less than or equal to approximately 1.0°C in Normal Operating Mode.

    MR Image quality may be compromised if the area of interest is the same or relatively close to the position of the device. Therefore, it may be necessary to optimize the MR imaging parameters for the presence of this implant.

    POTENTIAL ADVERSE EVENTS

    Potential adverse events that may occur during or after a procedure placing this device include, but are not limited to:

    • Air embolus
    • Allergic dye reaction
    • Allergic drug reaction
    • Anesthesia reactions
    • Apnea
    • Arrhythmia
    • Bacterial endocarditis
    • Bleeding
    • Cardiac perforation
    • Cardiac tamponade
    • Chest pain
    • Device embolization
    • Device erosion
    • Death
    • Fever
    • Headache/migraine
    • Hemolysis
    • Hematoma
    • Hypertension
    • Hypotension
    • Infection
    • Myocardial infarction
    • Palpitations
    • Partial obstruction of aorta
    • Partial obstruction of pulmonary artery
    • Pericardial effusion
    • Pericarditis
    • Peripheral embolism
    • Pleural effusion
    • Pulmonary embolism
    • Re-intervention for device removal
    • Respiratory distress
    • Stroke
    • Thrombus
    • Transient ischemic attack
    • Valvular regurgitation
    • Vascular access site injury
    • Vascular occlusion
    • Vessel perforation

This site uses cookies to improve your experience.

To find out more please read our Privacy and Cookies policy.

Ok

YOU ARE ABOUT TO LEAVE
www.structural­heart­solutions.com

You are now leaving www.structuralheartsolutions.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.